Introduction
5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a product of the 5-lipoxygenase pathway, along with leukotrienes B 4 and C 4 . It is formed by the NADP + -dependent oxidation of 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5S-HETE) by 5-hydroxyeicosanoid dehydrogenase [1] , which is highly expressed in a variety of both inflammatory and structural cells [2] . The formation of 5-oxo-ETE is regulated by the availability of the cofactor NADP + , which is normally present at very low intracellular concentrations, but is dramatically elevated under conditions of oxidative stress, activation of the respiratory burst, and cell death [3] . 5-Oxo-ETE is a potent activator of human and monkey [4] eosinophils and is the only 5-lipoxygenase product with potent chemoattractant effects for these cells [5] . It acts via the selective OXE receptor, which is highly expressed on eosinophils and to a lesser extent on neutrophils and macrophages [6] . Intradermal injection of 5-oxo-ETE in humans results in the infiltration of eosinophils into the skin and this response is enhanced in asthmatic subjects [7] .
The potent chemoattractant effects of 5-oxo-ETE on eosinophils, suggest that it may be an important proinflammatory mediator in eosinophilic disorders such as asthma and allergic rhinitis. For this reason, we sought to develop selective antagonists against the human OXE receptor, using calcium mobilization in human neutrophils as a screening test. We tested a series of indoles containing two side chains, one mimicking carbons 1-5 of 5-oxo-ETE and the other, carbons 15-20 of 5-oxo-ETE. We found that an indole containing a hexyl group in the 2-position and a 5-oxovalerate group in the 3-position selectively blocked 5-oxo-ETE-induced calcium mobilization. Modification of this compound led to the identification of the chiral compound 230 (Fig. 1) as a potent and selective OXE receptor antagonist [8] , with the antagonist activity residing almost exclusively in the S-enantiomer (S230) [9] .
To determine whether S230 may be useful therapeutically it will have to be tested in an animal model. Orthologs of the OXE receptor exist in many species but unfortunately not in rodents. We initially investigated the possibility that cats, which have an OXE receptor ortholog and are quite susceptible to asthma, might be a suitable experimental model for this purpose. Although 5-oxo-ETE is an extremely potent activator of feline eosinophils, 230 is only a weak antagonist in this species, presumably because of significant differences between the human and feline receptors [10] . We therefore plan to test 230 in monkeys. To do this it is first important to understand its metabolism and to establish whether adequate blood levels can be achieved. In an initial study we investigated the pharmacokinetics and metabolism of racemic 230, as at the time that the study was initiated we did not have a procedure for the synthesis of sufficient amounts of the pure S-enantiomer. We found that 230 is a potent OXE receptor antagonist in vitro in monkeys and that it rapidly appears in the blood, along with a number of metabolites, following oral administration [4] . Chiral analysis of 230 recovered from the blood revealed that the S-enantiomer was depleted more rapidly than the R-enantiomer. Although this study was not designed to follow the time courses of the metabolites, x1-and x2-oxidation products were identified by comparison with authentic standards in a blood sample taken 4 h after administration of 230. A number of other unidentified metabolites were also detected, including a pair of isomers that exhibited distinct chromatographic behaviour and may have been formed due to hydroxylation of the hexyl side chain a or possibly b to the indole moiety (see Fig. 1 for designation of the different carbons of the hexyl group).
The objective of the current study was to investigate the pharmacokinetics and metabolism of the active S-enantiomer of 230, which was made possible by a novel synthetic procedure that we recently developed [11] . We particularly wanted to conclusively identify the putative a-or b-hydroxy metabolite referred to above and to examine its antagonist activity, as hydroxylation of 5-oxo-ETE in the equivalent (x6) position does not abolish its agonist activity [2] .
Materials and methods

Animal experiments
Three female cynomolgus monkeys weighing between 4.9 and 5.3 kg and housed at INRS-Institut Armand-Frappier, Laval, Quebec, were used for these studies. All experiments were performed in accordance with the guidelines of the Canadian Council on Animal Care and were approved by the local institutional animal care committee. S230, synthesized as described previously [11] , was dissolved in EtOH at a concentration of 75 mg/mL and the appropriate volume added to 10 volumes of 20 mM NaHCO 3 and the mixture vortexed. The resulting suspension (4.4 mL/kg) was administered to three monkeys by oral gavage at a dose of 30 mg/kg. Blood samples were collected in heparinized tubes just prior to gavage (1 mL) and 1, 4, 8, 12 , and 24 h after gavage (4.5 to 5 ml for each time point, depending on the weight of the monkey). After centrifugation, plasma samples were frozen and stored at À80°C.
Analysis of S230 and its metabolites by RP-HPLC
Solvents used for chromatographic analysis were purchased from Fisher Scientific, Markham, ON, Canada. Plasma samples were thawed and diluted by the addition of MeOH (2 volumes), followed by addition of the internal standard (1 mg 5-(5-chloro-1-methyl-2-(5-methylhexyl)-1H-indol-3-yl)-3-methyl-5-oxopentanoate; identical to 230 except that it contains an isoheptyl group instead of a hexyl group; synthesized as previously described [4] ). After storing overnight at À80°C the samples were thawed and centrifuged. The concentration of MeOH was adjusted to 30% by the addition of water and each sample was loaded onto a Sep-Pak C18 cartridge (Waters Corporation, Milford Massachusetts) [12] , which was washed with 30% MeOH prior to the elution of indole metabolites with 100% MeOH. After evaporation of the solvent using a rotary evaporator the residue was dissolved in 30% MeOH and analyzed by precolumn extraction/RP-HPLC [13] . The precolumn was a C18 SecurityGuard cartridge (3.2 Â 8 mm ID) from Phenomenex, Torrance, CA, whereas the analytical column was a Kinetex C18 column (5 lm particle size; 4.6 mm Â 250 mm; Phenomenex;) with a linear gradient between 35 and 66% MeCN containing 0.02% HOAc over 62 min at a flow rate of 1 ml/min and a column temperature of 35°C. Fractions corresponding to peaks of interest were collected and combined for subsequent analysis by LC-MS/ MS.
The concentrations of 230 and its major metabolites were determined by measuring the ratios of their peak areas with that of the internal standard. The identities of the metabolites that were Peak x from panel A was subjected to chiral-HPLC on a Cellulose-2 column as described in Section 2 with a mobile phase of hexane/EtOH/HOAc (85:15:0.1). C: Peak y from panel E was subjected to chiral-HPLC on a Cellulose-2 column with a mobile phase of hexane/EtOH/HOAc (93:7:0.1). D: The effects of S230 and diastereomers x1 (▲), x2 (D), y1 (d) and y2 (O), purified as shown in panels A to C, on 5-oxo-ETE-induced calcium mobilization in human neutrophils were determined as described in Section 2. 
Chiral HPLC
Chiral HPLC was carried out using a Lux Cellulose-2 column (5 mm particle size; 250 Â 4.6 mm; Phenomenex). The mobile phases used are described in the legends to the relevant figures. A flow rate of 1 mL/min and a column temperature of 45°C were used throughout.
Identification of S230 metabolites by LC-MS/MS
Fractions corresponding to the HPLC peaks shown in Fig. 5A were collected, with identical fractions from different time points being pooled. These fractions were then analyzed by LC/MS/MS using a model 1100 HPLC system (Agilent Technologies, Santa Clara, CA) connected to an LTQ Velos Orbitrap high resolution mass spectrometer via a heated electrospray ionization source (Thermo Scientific, San Jose, CA). Chromatographic separation was performed using a Phenomenex Kinetex C18 column (2.6 lm particle size; 50 mm Â 2.1 mm) at the flow rate of 0.3 mL/min and a column temperature of 25°C. 
Evaluation of potencies of a-hydroxy-230 diastereomers in human neutrophils
The antagonist effects of a-hydroxy-230 diastereomers on 5-oxo-ETE-induced calcium mobilization in human neutrophils were examined as described previously [8] . Neutrophils prepared by dextran sedimentation and centrifugation over FicollÀPaque (GE Healthcare, Mississauga, ON, Canada) were loaded with indo-1 AM (ThermoFisher Scientific, Waltham, MA) and placed in a thermostatted cuvette at 37°C. After stabilization of baseline fluorescence, the a-hydroxy compound was added. 5-Oxo-ETE (10 nM;
synthesized as previously described [14] ) was added 2 min later followed 1 min later by digitonin (final concentration 0.1%). Fluorescence was measured using a Cary Eclipse spectrofluorometer (Agilent Technologies, Santa Clara, CA).
Chemistry
All reagents and solvents used for chemical synthesis were purchased from Sigma-Aldrich, Saint Louis, MO. All reactions were carried out under an argon atmosphere using dried, nitrogen-purged glassware and dry solvents. Reaction progress was monitored using Merck TLC Silica gel 60 F 254 plates. The plates were visualized using 254 nm UV light, iodine chamber and anisaldehyde dip where appropriate, followed by gentle warming. NMR spectra were recorded on a BRUKER AMX 400 MHz spectrometer at rt in CDCl 3 , using TMS as an internal standard. The following abbreviations are used for the description of NMR spectra: s-singlet; d-doublet; t-triplet; q-quartet; dd-doublet of doublets and m-multiplet. High resolution mass spectrometry (HRMS) was performed using an AccuTOF mass spectrometer with positive ion ESI mode and DART as an ion source. The purity of all tested compounds was determined to be >95% by a combination of HPLC, NMR and HRMS.
X-ray single crystal diffractometry
Single crystals suitable for X-ray diffraction were mounted on a Mitegen micromesh mount with the help of a trace of mineral oil. Data were collected on a Rigaku R-axis curved image plate diffractometer equipped with a MicroMax002 + high-intensity copper Xray source with confocal optics and examined with Cu Ka radiation (k = 1.54184 Å). Data were collected using the d⁄TREK option of CrystalClear (Rigaku, The Woodlands, TX). All data sets were processed using HKL3000 [15] and were corrected for absorption and scaled using Scalepack [15] . The space group was assigned using XPREP from the Shexltl suite of programs (SHELXTL (2003) Bruker Advanced X-ray Solutions, Bruker AXS Inc., Madison, Wisconsin: USA) and the structures were solved by direct methods with SHELXS [16] and refined by full matrix least squares against F 2 with all reflections using SHELXL-2014 [17] using the graphical user interface ShelXle [18] . H atoms attached to carbon and oxygen atoms were positioned geometrically and constrained to ride on their parent atoms, with carbon hydrogen bond distances of 0.95 Å for aromatic and alkene C-H, and 0.99 and 0.98 Å for aliphatic CH 2 and CH 3 moieties. U iso (H) values were set to 1.5 times U eq (-C/O) for methyl and hydroxyl hydrogen atoms, and to 1. 
To a stirred solution of 5-chloro-1-methyl-1H-indole-2-carbal dehyde (1) (1.675 g, 8.651 mmol) in THF (25 mL) was added pentyl magnesium bromide (2) (9 mL, 2.0 M solution in Et 2 O) at À78°C dropwise over a period of 5 min. The reaction mixture was stirred at À78°C for 20 min and then at rt for 15 min. Aqueous NH 4 Cl (20 mL) was added and the organic layer was extracted with EtOAc (3 Â 25 mL). The combined organic extracts were washed with brine (50 mL), dried over Na 2 SO 4 , and the solvents were evaporated to obtain the crude mixture. Silica gel (from VWR International, Radnor, PA) column chromatography (15% EtOAc/hexane) afforded the product as a yellow solid (2.089 g, 91% 
2-(1-((tert-Butyldimethylsilyl)oxy)hexyl)-5-chloro-1-methyl-1H-indole (4)
To a stirred solution of 1-(5-chloro-1-methyl-1H-indol-2-yl)he xan-1-ol (3) in CH 2 Cl 2 (8 ml) was added TBDMSCl (200 mg, 1.327 mmol) followed by imidazole (150 mg, 2.203 mmol) and the reaction mixture was stirred at rt for 14 hÁH 2 O (8 mL) was added and the organic layer was extracted with CH 2 Cl 2 (3 Â 5 mL). The combined organic extracts were washed with aqueous NaHCO 3 (20 mL), dried over Na 2 SO 4 , concentrated to dryness, and purified using silica gel column chromatography (5% EtOAc in hexane) to obtain the product as a pale-yellow viscous oil (290 mg, 87% 
To a 100 mL round bottom flask containing 2-(1-((tert-butyldi methylsilyl)oxy)hexyl)-5-chloro-1-methyl-1H-indole (4) (127 mg, 0.334 mmol) in CH 2 Cl 2 (16 mL) was added methyl 5-chloro-3-methyl-5-oxopentanoate (5) (80 mg, 0.448 mmol) in CH 2 Cl 2 (1 mL). The solution was cooled to 0°C, and Me 2 AlCl (0.43 mL, 1.0 M solution in hexanes) was added slowly over a period of 5 min. The reaction mixture was stirred at 0°C for 1 h and then at rt for 2 h. Aqueous NaHCO 3 solution (10 mL) was then added to quench the reaction. The aqueous layer was extracted with EtOAc (3 Â 8 mL), and the combined organic extracts were washed with brine (20 mL), dried over Na 2 SO 4 , the volatiles removed under reduced pressure, and the resulting crude product was purified using silica gel column chromatography (2% EtOAc/hexane) to afford compound 6 as a pair of diastereomers (67 mg, 38% 
To a stirred solution of methyl 5-(2-(1-((tert-butyldimethylsi lyl)oxy)hexyl)-5-chloro-1-methyl-1H-indol-3-yl)-3-methyl-5-oxo pentanoate (6) (10 mg, 0.0191 mmol) in CH 3 CN (5 mL) was added HFÁPyridine (0.1 ml, 30% pyridine, 70% HF) at 0°C. The reaction mixture was allowed to warm to rt and stirred for 30 min. Aqueous NaHCO 3 solution (5 mL) was added, the aqueous layer was extracted with EtOAc (3 Â 5 mL), and the combined organic extracts were dried over Na 2 SO 4 . Evaporation of the solvents in vacuo gave the crude product as a pale yellow solid that was dissolved in THF (2.5 mL) and H 2 O (0.6 mL). To this solution was added LiOHÁH 2 O (32 mg, 0.763 mmol) and MeOH (0.1 mL). The reaction mixture was stirred at rt for 14 hÁH 2 O (5 mL) was added and the aqueous layer was extracted with EtOAc (3 Â 5 mL), and the organic extract dried over Na 2 SO 4 , concentrated to dryness, and the product purified using silica gel column chromatography (4% MeOH/CH 2 Cl 2 ) to isolate the product as a pair of diastereomers (pale-yellow viscous oil, 6.1 mg, 80% over two steps 
(S)-
To a stirred solution of (S)-BINOL (503 mg, 1.757 mmol) in tBuOMe (52 mL) was added Ti(O-iPr) 4 (3.5 mL, 11.945 mmol) dropwise at rt, and the resulting red solution was stirred for 30 min. In another flask, containing a solution of BDMAEE (5.3 mL, 27.813) in tBuOMe (52 mL) was added freshly prepared pentyl magnesium bromide (27.094 mmol in 20 mL THF) at 0°C. The resulting cloudy suspension was stirred at 0°C for 35 min. The mixture from the former flask was transferred slowly into the latter at À15°C. The reaction mixture was allowed to warm to rt and then stirred for 1 h. After that, 5-chloro-1-methyl-1H-indole-2-carbaldehyde (1) (1.553 g, 8.020 mmol) in THF (20 mL) was added dropwise at -15°C over a period of 5 min. The reaction mixture was allowed to warm to rt and stirred for 36 h. The reaction was quenched by adding aqueous NH 4 Cl solution (60 mL). The two layers were separated, the aqueous layer was extracted with EtOAc (3 Â 20 mL), and the combined organic extracts were washed with brine (60 mL), dried over Na 2 SO 4 , filtered, and the solvents removed under reduced pressure. The brown viscous crude product was purified using silica gel column chromatography (10% EtOAc/hexane) to afford the product as a yellow solid (1.027 g, 48%). (See the experimental of the racemic compound 2 for the spectral properties). Using chiral HPLC, the %S enantiomer was determined to be 97.1. Recrystallization using hexane-methanol improved the enantiomeric purity to 100%.
The procedure was identical to that described for 2-(1-((tert-b utyldimethylsilyl)oxy)hexyl)-5-chloro-1-methyl-1H-indole (4).
To a stirred solution of (S)-2-(1-((tert-butyldimethylsilyl)oxy)h exyl)-5-chloro-1-methyl-1H-indole (8) (47 mg, 0.124 mmol) in CH 2 Cl 2 (8 mL) was added methyl (R)-5-chloro-3-methyl-5-oxopentanoate (27 mg, 0.151 mmol) in CH 2 Cl 2 (1.1 mL). The solution was cooled to 0°C, and Me 2 AlCl (0.14 mL, 1.0 M solution in hexanes) was added over 15 min. The reaction mixture was then stirred at 0°C for 1 h and then at rt for a further 24 h. Aqueous NaHCO 3 (5 mL) was added and the aqueous layer was extracted with EtOAc (3 Â 5 mL). The combined organic extracts were washed with brine (10 mL), dried over Na 2 SO 4 , concentrated to dryness, and the product was purified using silica gel column chromatography (2% EtOAc/hexane) to afford a yellow viscous oil containing the acylated product along with some inseparable impurities. The mixture, which was used as is without further purification, was dissolved in CH 3 CN (7 mL), followed by the addition of HF-Pyridine (0.18 mL, 30% pyridine, 70% HF) at 0°C. The reaction mixture was stirred at rt for 30 min. Aqueous NaHCO 3 (4 mL) was added and the aqueous layer was extracted with EtOAc (3 Â 4 mL) and the organic extract dried over Na 2 SO 4 . After removal of the solvents in vacuo the crude product was passed through a short silica gel column and the combined filtrate was concentrated to obtain a yellow viscous oil that was subjected to ester hydrolysis under basic conditions. The yellow viscous oil was dissolved in THF (2 mL) and H 2 O (0.5 mL). To the stirred solution was added LiOHÁH 2 O (24 mg, 0.572 mmol) and a drop of MeOH. The reaction mixture was stirred at rt for 16 hÁH 2 O (10 mL) was added and the aqueous layer was extracted with EtOAc (3 Â 4 mL), and the organic extract dried over Na 2 SO 4 , concentrated to dryness, and the product was purified using silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to obtain the final product as a yellow viscous oil, 8.6 mg, 18% over three steps 
(R)-
The procedure was identical to that described for (S)-1-(5-chlo ro-1-methyl-1H-indol-2-yl)hexan-1-ol (7) except (R)-BINOL was used instead of (S)-BINOL.
(S)-
The procedure was identical to that described for (S)-5-(5-chloro-2-((S)-1-hydroxyhexyl)-1-methyl-1H-indol-3-yl)-3-methy l-5-oxopentanoic acid (a(S)-OH-S230).
Results
Identification of a-hydroxy metabolites of 230
We previously detected two isomeric forms of a plasma metabolite of 230 (metabolites d and e in Fig. 2A ) with retention times between those of 230 and x2-OH-230. Mass spectral evidence suggested that these isomers might be formed by hydroxylation of the alkyl side chain a, or possibly b, to the indole.
However, we were unable to conclusively identify these isomers because of the lack of an authentic synthetic standard for comparison. To address the hypothesis that metabolites d and e are two stereoisomers of a-OH-230 we prepared a mixture of the 4 possible diastereomers of this compound 1 as shown in Fig. 3 . The a-OH centre was introduced using a Grignard reaction between 5-chloro-1-methyl-1H-indole-2-carbaldehyde (1) and pentyl magnesium bromide (2) . Because the free a-OH group was not tolerated in a FriedelCraft's reaction to introduce the 5-oxo-valerate side chain, it was first protected by conversion to a silyl ether (OTBDMS) derivative.
RP-HPLC of synthetic a-OH-230 gave two peaks, labeled x and y in Fig. 2B , which had retention times identical to those of plasma-1 ''a" is used to designate the carbon of the hexyl side chain adjacent to the indole moiety, whereas ''x2 00 is used to designate the penultimate carbon of the hexyl side chain. derived d and e (Fig. 2C) when chromatographed under the same conditions. Furthermore, d and e cochromatographed with x and y when equal amounts of these substances were mixed together Fig. 2D ). We previously showed [4] As it contains two chiral carbons, we would expect synthetic a-OH-230 to be a 1:1:1:1 mixture of four diastereomers. As pairs of enantiomers are unlikely to be separated by RP-or NP-HPLC, we would assume that product x is a mixture of either the aS-OH,SMe and aR-OH,R-Me diastereomers or alternatively the aS-OH,RMe and aR-OH,S-Me diastereomers, and vice versa for product y.
To investigate their antagonist potencies, we purified all four diastereomers by a combination of NP-and chiral HPLC. NP-HPLC of a-OH-230 gave 2 peaks, x and y, in the same elution order as with RP-HPLC (Fig. 4A) . Product x was separated into two diastereomers, x1 and x2, by chiral HPLC (Fig. 4B) . Chiral HPLC also separated product y into two diastereomers, y1 and y2 (Fig. 4C) . The effects of the above four diastereomers on 5-oxo-ETE-induced calcium mobilization are shown in Fig. 4D . Only y1 had appreciable antagonist activity with an IC 50 of 1.6 ± 0.3 mM, over 100 times higher than that of S230 (IC 50 , 13 ± 2 nM in these experiments).
The other three a-OH-230 diastereomers had only very weak effects, inhibiting calcium mobilization by between 4 and 9% at a concentration of 10 mM.
Identification of plasma metabolites of S230 in cynomolgus monkeys
To investigate the chirality of metabolites d and e and the time course for their formation we conducted in vivo experiments in cynomolgus monkeys. Because nearly all of the antagonist activity of 230 resides in the S enantiomer, we focused on S230, which was administered to three monkeys by oral gavage at a dose of 30 mg/ kg. Blood samples were obtained after 1, 4, 8, 12, and 24 h and S230 and its metabolites were extracted from plasma and analyzed by RP-HPLC. Fig. 5A shows the profile of S230 metabolites in plasma after 8 h (note that a shallower gradient was used for this chromatogram compared to that shown in Fig. 2A) . A substantial amount of e was formed from S230, but in contrast to racemic 230, very little d was detected. Since the chiral methyl group of the substrate is in the S configuration, this suggests that the ahydroxylation reaction is stereospecific, with the alkyl hydroxyl group being almost exclusively in either the R or S configuration.
Metabolite e should therefore be either aS-OH-S230 or aR-OH-S230. These diastereomers should be separable by RP-HPLC, but authentic standards would be required to distinguish between them.
In addition to the two x2-oxidized metabolites that we had previously identified [4] and a-OH-S230, we observed several other major metabolites of S230, including a and b, which were considerably more polar than x2-OH-S230 (Fig. 5A) . A minor product (c) was also observed after 8 h, but was much more prominent 1 h after administration of S230 (inset to Fig. 5A ). The polar metabolite b has an UV spectrum almost identical to that of metabolite e, with a maximum at 312 nm, compared to about 305 nm for 230 and its x2-oxidation products (Fig. 5B) , suggesting that it might also have an alkyl hydroxyl group a to the indole. The mass spectrum of b revealed an [MÀH] À ion at m/z 408.1571, compared to the theoretical value of m/z 408.1578 expected for a dihydroxy metabolite of 230 (mass accuracy, 1.7 ppm). The MS 2 fragmentation pattern of b (Fig. 5D) is very similar to that of authentic a-OH-230 (Fig. 2E) except that the ion formed by loss of H 2 O was observed at m/z 390 instead of 374, consistent with the presence of an additional hydroxyl group. The MS 3 fragmentation profile of the major ion in Fig. 5D at m/z 292 (Fig. 5E ) formed by loss of the alkyl side chain was virtually identical to that shown in Fig. 2F for a-OH-230. From these data we conclude that b is a hydroxy metabolite of a-OH-230, most likely a,x2-diOH-230.
Two additional major metabolites of S230 were also detected: c, which was prominent only at 1 h, and a, which was detected at all time points investigated. The UV spectra of a and c ( pattern for c had a single major ion at m/z 376 due to the characteristic loss of m/z 176 from a glucuronide (Fig. 5F ). The MS 3 spectrum of the latter ion (Fig. 5G) 
Pharmacokinetics of S230 and its metabolites
S230 and its metabolites were quantitated by RP-HPLC using an isoheptyl analog of S230, which has a longer t R than S230, as an internal standard. The identities of all compounds quantitated were confirmed by LC-MS/MS as well as by cochromatography when the authentic standards were available.
S230 rapidly appeared in the blood, reaching a maximal concentration of 32 mM within 1 h and then declining to about 11% of this level by 4 h and to 5% by 8 h (Fig. 6A) . Although they are quite high, these concentrations are lower than those that we previously reported for racemic 230 [4] , also shown in Fig. 6A for com- parison. In contrast, a biphasic pattern was observed with a-OH-S230, which reached maximal levels by 1 h, declined, and then rose again at 8 h (Fig. 6B) . As would be expected, the concentration of the dihydroxy metabolite of S230 rose more slowly, reaching a maximum by 8 h and then declining. x2-OH-S230 increased to maximal levels by 4 h and then declined, whereas the maximal level of its oxidation product x2-oxo-S230 was observed at 8 h (Fig. 6C) . The glucuronide metabolites of S230 both peaked at 1 h and then declined (Fig. 6D) . In contrast to S230 glucuronide, which dropped to very low levels by 4 h, the time course for x2-OH-S230 glucuronide was biphasic, with a second maximum being observed at 8 h.
Chiral synthesis of a-hydroxy diastereomers of S230
To determine the chirality of the a-hydroxyl group in metabolite e we synthesized both aS-OH-S230 and aR-OH-S230 using a previously reported method for the stereospecific addition of Grignard reagents to aromatic aldehydes [19] . Accordingly, (S)-BINOLmediated enantioselective addition of pentyl magnesium bromide (2) to the prochiral aldehyde 1 yielded the a-hydroxy compound, 97.1% of which was the S enantiomer 7 (Fig. 7) . The small amount of R-enantiomer was completely removed after recrystallization as demonstrated by chiral HPLC (Fig. 8B ) using conditions that completely separate the R and S enantiomers (Fig. 8A) . The absolute configuration of 7 was confirmed using single crystal X-ray diffractometry (Fig. 8C) . The a-OH group of 7 was protected using TBDMS to obtain 8. Friedel-Craft's acylation of 8 using the chiral acyl side chain 9 [11], followed by removal of the TBDMS with HF-pyridine and ester hydrolysis under basic conditions, afforded the desired 8 . Chiral HPLC and X-ray crystal structure of 7. Chiral HPLC of the racemic version of 7 (A) and crystallized synthetic 7 (S-enantiomer) (B) on a Cellulose-2 column using hexane/MeOH/HOAc (98:2:0.1) as the mobile phase at a flow rate of 1 ml/min and a column temperature of 45°C. C: X-ray crystal structure of 7. Thermal ellipsoids are set at the 50% probability level.
compound aS-OH-S230 with a chiral purity of 78% as determined by chiral HPLC.
The a(R)-hydroxy compound, aR-OH-S230, was prepared in a similar fashion as shown in Fig. 9 . The enantioselective addition of the Grignard reagent 2 to the aldehyde 1 in the presence of (R)-BINOL afforded the a-hydroxy compound, 97.3% of which was the R enantiomer 10. Compound 10 was then treated similarly to the S-enantiomer 7 to yield the final product aR-OH-S230 with a chiral purity of 72%.
Identification of metabolite e as aS-OH-S230
To determine the configuration of the a-hydroxy metabolite e we compared its chromatographic properties to those of the synthetic compounds aS-OH-S230 and aR-OH-S230. Initial studies revealed that with RP-HPLC the aR-OH diastereomer (labeled ''RS" in Fig. 10A ) has a shorter retention time than the aS-OH diastereomer (labeled ''SS" in the figure) . The t R of metabolite e under the same conditions was identical to that of aS-OH-S230 (Fig. 10B ) and this was confirmed by cochromatography of e with a mixture of the two synthetic a-hydroxy compounds (Fig. 10C ).
There appeared to be a very small peak (d) corresponding to the elution position of aR-OH-S230 (Fig. 10B) . We measured the area of this peak at all time points and in all cases it amounted to about 3% of the area of metabolite e (Fig. 10G) .
Similar experiments were performed using chiral HPLC. In this case, the t R of aS-OH-S230 was shorter than that of the corresponding aR-OH diastereomer (Fig. 10D) . The t R of e (Fig. 10E ) was identical to that of aS-OH-S230 and the two compounds cochromatographed with one another (Fig. 10F) . Furthermore, we analyzed metabolite e, purified by RP-HPLC using an acetonitrile gradient, by chiral HPLC at all time points investigated and did not detect any other diastereomers (data not shown). Therefore, we can conclude that e is identical to aS-OH-S230. Metabolite d derived from S230 is therefore probably identical to aR-OH-S230, although the amount detected is too small to be certain of this.
Discussion
In our previous studies we identified racemic 230 as a potent 5-oxo-ETE antagonist [8] that rapidly appears in the blood following oral administration to monkeys [4] . By preparing a series of potential metabolites of 230 by total chemical synthesis we identified x2-oxidation of the hexyl side chain as a major metabolic pathway for this compound. However, we also observed a number of additional metabolites, including a pair of isomeric compounds that displayed a bathochromic shift in their UV spectra compared to 230 (305 nm ? 311 nm), suggestive of a modification close to the indole chromophore. This was supported by mass spectral evi- dence showing that these metabolites possess an additional hydroxyl group in the alkyl side chain a or possibly b to the indole, but we were unable to confirm their identities due to the lack of authentic standards.
For the reasons discussed above we hypothesized that the isomeric metabolites d and e absorbing at 311 nm are a mixture of isomers of a-OH-230, which has 2 chiral carbons and therefore 4 possible diastereomers. We initially developed a procedure for the synthesis of a mixture of all four diastereomers. RP-HPLC of this mixture gave two peaks that cochromatographed with our novel metabolites and had identical MS 2 and MS 3 spectra, confirming the presence of the hydroxyl group on the alkyl side chain a to the indole.
We expected that addition of a hydroxyl group at the x-end of the hexyl group of 230 would reduce antagonist activity, consistent with the loss of agonist activity following x1-hydroxylation of 5-oxo-ETE [20] , and this proved to be the case [4] . However, it is more difficult to predict the effect of addition of a hydroxyl group a to the indole, which would be equivalent to the x6-position of 5-oxo-ETE. 5-Oxo-ETE can be hydroxylated in the x6-position by 15-lipoxygenase, resulting in the formation of 5-oxo-15S-HETE [21] , which, although not as potent as 5-oxo-ETE, is an OXE receptor agonist [5, 22] . In contrast, 5-oxo-ETE can be hydroxylated in the x9-position by platelet 12-lipoxygenase to give 5-oxo-12S-HETE, which was the first OXE receptor antagonist to be recognized [23] . It was therefore important to examine the antagonist activities of the four synthetic a-OH-230 diastereomers, which were purified by a combination of normal-phase and chiral HPLC. Interestingly, only one of these diastereomers, subsequently identified as aS-OH-S230 (Table 1) , displayed significant antagonist activity (IC 50 , 1.6 mM), being about 100 times less potent than S230 in inhibiting 5-oxo-ETE-induced calcium mobilization. This is similar to the IC 50 for x2-hydroxy-230 (1.4 mM) and a bit higher than that for x1-hydroxy-230 (0.27 mM) [4] .
Because an S-methyl group is required for appreciable antagonist activity it could be assumed that the active a-hydroxy metabolite of 230 has an S-methyl group. Of the three inactive diastereomers two would have an R-methyl group and would therefore be expected to have little or no activity. However, the remaining inactive diastereomer would have an S-methyl group and either an R or an S a-hydroxyl group, indicating that only one of these configurations is compatible with antagonist activity.
The impact of the chirality of the a-hydroxyl group could possibly be due to an effect on the orientation of the alkyl group, which we have shown to be very important for interaction with the OXE receptor [24] . There could also be hydrogen bonding between the a-hydroxyl group and the oxo group, which would likely be affected by its chirality. For further studies on the pharmacokinetics and metabolism of 230 we focused on the active S-enantiomer (S230), which is over 400 times more potent than the R-enantiomer (R230) [8, 9] . To provide the gram-amounts of antagonist that would be required for this and subsequent in vivo studies we developed a novel procedure using the chiral reagent (S)-Tol-BINAP for the synthesis of the chiral acyl side chain of S230 [11] . This permitted the synthesis of substantial amounts of this compound with high (>98%) enantiomeric purity.
The pharmacokinetic profile of S230 is quite similar to that which we previously observed for racemic 230 [4] except that the plasma concentrations were lower at all time points, peaking at 32 mM after 1 h, compared to 87 mM for racemic 230. This could be explained, at least in part, by differences in the rates of metabolism or intestinal uptake between S230 and R230, consistent with our finding of higher plasma levels of the R enantiomer following oral administration of racemic 230 [4] .
Analysis of the plasma metabolites of S230 by RP-HPLC revealed a number of peaks that we had not previously identified (a, b, and c), and only one significant peak (e) for a-OH-S230 in contrast to the two peaks (d and e) observed with racemic 230. Since e is derived from S230 it could be either aS-OH-S230 or aR-OH-S230, which should be separable by RP-HPLC, as they are not mirror images of one another. This suggests that the a-hydroxylation reaction is stereospecific. To test this hypothesis, and to determine whether the a-hydroxy metabolite of S230 in plasma is the one with antagonist activity, we prepared both of the above diastereomers using (S)-BINOL and (R)-BINOL and confirmed the absolute chirality of the products by X-ray diffractometry. Comparison of the chromatographic properties of the resulting authentic standards clearly indicated that both metabolite e derived from S230 and the a-hydroxy-230 diastereoisomer with antagonist activity are identical to aS-OH-S230. It is interesting that this highly stereoselective hydroxylation reaction results in the formation of the only diastereomer with significant antagonist activity.
The site at which the a-hydroxylation reaction occurs in the monkey is not clear. In our previous studies we did not detect a-OH-230 following incubation of racemic 230 with monkey liver microsomes in the presence of NADPH, which instead converted this compound almost exclusively to x2-and to a much lesser extent, x1-oxidation products [4] . We have subsequently examined microsomes from other sources, including kidney, intestine, and lungs but did not detect a-hydroxylation activity in the presence of NADPH (data not shown). Neither did we detect such products as a result of incubating 230 with either plasma or intact leukocytes. One possibility might be that this reaction is catalyzed by bacteria in the gastrointestinal tract.
Although benzylic hydroxylation is quite well known [25, 26] and is an important step in the formation of noradrenaline, there are few examples in the literature of a-hydroxylation of alkylindoles. The bacterial enzyme indolyl-3-alkane a-hydroxylase, isolated from Pseudomonas, has been shown to catalyze ahydroxylation of the side chain in the 3-position of tryptophan [27, 28] . This is not a direct hydroxylation, but rather proceeds by the initial abstraction of 2 hydrogens, one on the indole nitrogen, and the other on the side chain carbon adjacent to the indole ring. This results in the formation of a 3-alkylidene indoline intermediate that undergoes the 1,4 addition of H 2 O to give the a-hydroxy product [29] . However, 2-alkylindoles such as S230 would not be a substrate for such a series of reactions.
In addition to aS-OH-S230 we identified several other novel metabolites of S230. One of these (metabolite b) was formed by a combination of a-and x-oxidation (Fig. 11) . Although we cannot be certain of the location of the second hydroxyl group, it is highly likely that it is in the x2-position, because x2-hydroxylation is a major pathway for the metabolism of S230. The resulting product, aS,x2-dihydroxy-S230 could be formed from either aS-OH-S230 or x2-OH-S230.
We also detected glucuronide metabolites of S230 and hydroxy-S230, presumably x2-OH-S230. The S230 metabolite would clearly be an acyl glucuronide, as this compound does not have a free hydroxyl group. In contrast, x2-OH-S230 could be converted to either an acyl or an ether glucuronide, or to both. At all time points Table 1 Synthetic and biological a-hydroxy metabolites of 230. The IC 50 values were determined from the data shown in Fig. 4D later than 1 h, the concentrations of x2-OH-S230 glucuronide(s)
were considerably higher than those of S230 glucuronide, even when the plasma concentrations of S230 were much higher than its x2-hydroxy metabolite, which might be consistent with the glucuronide being in a different (i.e. ether) position, resulting in a more stable metabolite.
Overall, the combined concentrations of S230 metabolites remained between 2 and 3 mM over the first 8 h and then slowly declined, in contrast to S230, which declined fairly rapidly after reaching high initial levels by 1 h. By 8 h, the combined amounts of S230 metabolites exceeded that of S230 itself. Nevertheless, its concentration at this time was still greater than 1.5 mM, over 100 times higher than its IC 50 (13 nM) for inhibition of 5-oxo-ETEinduced calcium mobilization in vitro. Multiple dosing with S230 (e.g. every 8 h) may be required to achieve therapeutic levels over a period of 24 h in future in vivo experiments.
In conclusion, we have identified a novel stereoselective ahydroxylation pathway for the metabolism of a 2-alkylindole antagonist in primates. The aS-hydroxy product of this pathway still retains some antagonist activity, albeit considerably reduced, in contrast to the corresponding aR-hydroxy compound, which is virtually inactive. Thus S230 is metabolized in vivo by a combination of a-hydroxylation, x2-hydroxylation and glucuronidation. In spite of its metabolism by these pathways, plasma levels of S230 well in excess of its in vitro IC 50 value were maintained for 8 h. These results raise the possibility that either S230 itself or a related compound modified to resist hydroxylation, might be a useful therapeutic agent in eosinophilic disorders such as asthma. Studies are currently underway in primate models of allergic disease to test this hypothesis.
Database link
Data for the crystal structure of compound 7 has been deposited with the Cambridge Crystallographic Data Centre (deposition number, CCDC 1527527).
